Acute nasal care Target audiology and ENT device distributors with LATERA as a minimally invasive solution for nasal valve collapse, addressing a prevalent nasal obstruction condition affecting over 20 million patients in the U.S.

Strategic acquisition Leverage the history of acquisition by Entellus Medical and the company’s focused nasal implant portfolio to approach potential distributors or OEM partners seeking a proven鼻 obstruction platform and a scalable product line.

Clinical validation Highlight the 1-year first-in-human data from the LATERA implant to demonstrate safety and efficacy, supporting conversations with hospital systems and surgeons about adopting a durable, absorbable nasal support device.

Growth potential Position opportunities around expanding reimbursement readiness and KOL adoption to accelerate market penetration, given current revenue under 10M and a solid funding history including a $72M raise and strategic financing.

TECH & reach Emphasize the digital readiness and patient outreach capabilities reflected in the tech stack (PWA, cloud, maps) to propose integrated sales and service platforms for clinics, enabling streamlined product education, order placement, and post-sale support.